Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitnib in Relapsed/Refractory Indolent T/NK-Cell Lymphomas
NCT06716658Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in T-cell lymphoma, natural killer cell lymphoma, T-cell large granular lymphocytic leukemia (T-LGLL), NK-cell large granular lymphocyte leukemia (NK-LGLL), cutaneous T-cell lymphoma (CTCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Dec 2024; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
T-cell lymphomanatural killer cell lymphomaT-cell large granular lymphocytic leukemia (T-LGLL)NK-cell large granular lymphocyte leukemia (NK-LGLL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT06716658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716658.